Sanara MedTech Inc.SMTIEarnings & Financial Report
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
SMTI Q4 FY2025 Key Financial Metrics
Revenue
$27.5M
Gross Profit
$25.6M
Operating Profit
$6.5M
Net Profit
$-1.6M
Gross Margin
93.2%
Operating Margin
23.5%
Net Margin
-5.9%
YoY Growth
4.6%
EPS
$-0.32
Sanara MedTech Inc. Q4 FY2025 Financial Summary
Sanara MedTech Inc. reported revenue of $27.5M (up 4.6% YoY) for Q4 FY2025, with a net profit of $-1.6M (up 5.3% YoY) (-5.9% margin). Cost of goods sold was $1.9M, operating expenses totaled $19.2M.
Key Financial Metrics
| Total Revenue | $27.5M |
|---|---|
| Net Profit | $-1.6M |
| Gross Margin | 93.2% |
| Operating Margin | 23.5% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Sanara MedTech Inc. Q4 FY2025 revenue of $27.5M breaks down across 2 segments, led by Soft Tissue Repair Products at $24.7M (89.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Soft Tissue Repair Products | $24.7M | 89.9% |
| Bone Fusion Products | $2.8M | 10.2% |
Sanara MedTech Inc. Revenue by Segment — Quarterly Trend
Sanara MedTech Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Soft Tissue Repair Products and Bone Fusion Products) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Soft Tissue Repair Products | $24.7M | $23.4M | $22.7M | $20.5M |
| Bone Fusion Products | $2.8M | $2.9M | $3.1M | $2.9M |
Sanara MedTech Inc. Annual Revenue by Year
Sanara MedTech Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $103.1M).
Sanara MedTech Inc. Quarterly Revenue & Net Profit History
Sanara MedTech Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $27.5M | +4.6% | $-1.6M | -5.9% |
| Q3 FY2025 | $26.3M | +21.5% | $-30.4M | -115.5% |
| Q2 FY2025 | $25.8M | +28.1% | $-2.0M | -7.8% |
| Q1 FY2025 | $23.4M | +26.4% | $-3.5M | -15.1% |
| Q4 FY2024 | $26.3M | +48.7% | $-1.7M | -6.5% |
| Q3 FY2024 | $21.7M | +35.2% | $-2.9M | -13.2% |
| Q2 FY2024 | $20.2M | +28.0% | $-3.5M | -17.4% |
| Q1 FY2024 | $18.5M | +19.4% | $-1.8M | -9.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.5M | $20.2M | $21.7M | $26.3M | $23.4M | $25.8M | $26.3M | $27.5M |
| YoY Growth | 19.4% | 28.0% | 35.2% | 48.7% | 26.4% | 28.1% | 21.5% | 4.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $70.9M | $73.4M | $88.5M | $88.1M | $96.4M | $98.8M | $71.1M | $72.9M |
| Liabilities | $27.9M | $32.0M | $49.1M | $49.2M | $59.7M | $63.4M | $64.9M | $67.0M |
| Equity | $43.3M | $41.7M | $39.8M | $39.4M | $36.7M | $35.4M | $6.1M | $5.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.6M | $-1.4M | $2.1M | $932047 | $-2.0M | $2.7M | $2.2M | $3.9M |